<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04490031</url>
  </required_header>
  <id_info>
    <org_study_id>Hukm</org_study_id>
    <nct_id>NCT04490031</nct_id>
  </id_info>
  <brief_title>Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)</brief_title>
  <official_title>Randomized Control Study Evaluating Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Kebangsaan Malaysia Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiti Kebangsaan Malaysia Medical Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of
      Ketamine will be compared to the standard sedation in our center, which is Midazolam in
      combination with Pethidine as analgesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blinded study whereby both the surgeons and patients are blinded from the
      sedative agent used. Patients admitted to UKMMC requiring ERCP will randomized into 2 groups
      after evaluating the inclusion and exclusion criteria. Patients will be divided into two
      arms, Midazolam and Ketamine group respectively. Before the initiation of the the scope,
      patient would be given specified dose of sedation accordingly. All the parameters and outcome
      would be measured during and after the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Both the patients and surgeon will be blinded from knowing the sedative agent</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>depth of sedation</measure>
    <time_frame>1 hour</time_frame>
    <description>based on Ramsay Sedation Scale, from a scale of 1-6.
Patient is anxious and agitated or restless, or both
Patient is co-operative, oriented, and tranquil
Patient responds to commands only
Patient exhibits brisk response to light glabellar tap or loud auditory stimulus
Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus
Patient exhibits no response The aim of sedation is a score of 3-4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>completion rate</measure>
    <time_frame>1 hour</time_frame>
    <description>to evaluate completion rate between Ketamine and Midazolam group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgeon satisfaction score</measure>
    <time_frame>within 4 hours after completion of ERCP</time_frame>
    <description>subjective scoring of surgeon regarding overall experience of the ERCP from a score of 0-10.
0- poor, 5- moderate, 10- excellent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction score</measure>
    <time_frame>within 4 hours after completion of ERCP</time_frame>
    <description>subjective scoring of patients regarding overall experience of the ERCP from a score of 0-10.
0- poor, 5- moderate, 10- excellent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate the occurrence of hypertension, hypotension, bradycardia, tachycardia, hypoxia, respiratory rate abnormality, nausea, vomiting and emergence symptoms</measure>
    <time_frame>24 hours</time_frame>
    <description>recording the adverse events of each sedation.
Hypotension: defined as a systolic blood pressure drop greater than 20mmHg to a value less than 90mmHg
Hypertension: defined as a systolic blood pressure increase greater than 20mmHg or to a value more than 140mmHg
Bradycardia: defined as heart rate less than 50 after the initiation of sedation or decrease in heart rate more than 20 beats per minute
Tachycardia: defined as heart rate more than 100 after the initiation of sedation or increase in heart rate more than 20 beats per minute
Hypoxia: defined by oxygen saturation less than 95%
Respiratory rate abnormality
Nausea, vomiting, emergence symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Ketamine Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Midazolam group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard sedation for ERCP in UKMMC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Hydrochloride</intervention_name>
    <description>patient in Ketamine group will be given Ketamine as sedative agent</description>
    <arm_group_label>Ketamine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Malaysian citizens of who is able to give valid consent

          -  Patient planned for ERCP (either emergency or elective)

        Exclusion Criteria:

          -  Known hypersensitivity towards Ketamine or Midazolam

          -  Patient refusal to participate or unable to give consent

          -  Increased intracranial pressure, acute stroke (&lt;3 months), intracranial haemorrhage
             (&lt;3 months)

          -  Uncontrolled hypertension (BP&gt;160/100) and tachycardia (Heart rate &gt;120)

          -  Acute myocardial infarction, acute coronary syndrome (&lt;3 months)

          -  Tachyarrythmia

          -  Pregnancy

          -  IVDU or substance abuse patient

          -  Patient with history of hallucination

          -  Child's Pugh Class C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Chik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiti Kebangsaan Malaysia Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norma mohamad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiti Kebangsaan Malaysia Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zamri Zuhdi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiti Kebangsaan Malaysia Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Azlanudin Azman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiti Kebangsaan Malaysia Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muhammad Hafiz Ismail, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiti Kebangsaan Malaysia Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad Hafiz Ismail, MBBS</last_name>
    <phone>6016 3354384</phone>
    <email>muhdhafizismail88@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ian Chik, MD</last_name>
    <phone>6012 3243404</phone>
    <email>ianchikmd@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Kebangsaan Malaysia Medical center</name>
      <address>
        <city>Bandar Tun Razak</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zamri Zuhdi, MD</last_name>
      <phone>6019 2436634</phone>
      <email>zamriz7582@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ian Chik, MD</last_name>
      <phone>0123243404</phone>
      <email>ianchikmd@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zamri Zuhdi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Azlanudin Azman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian Chik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norma Mohamad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muhammad Hafiz Ismail, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

